WO2000028010A3 - Die gentechnische prägung von zellen und ihre verwendung zur prophylaxe und therapie von erkrankungen - Google Patents

Die gentechnische prägung von zellen und ihre verwendung zur prophylaxe und therapie von erkrankungen Download PDF

Info

Publication number
WO2000028010A3
WO2000028010A3 PCT/EP1999/007902 EP9907902W WO0028010A3 WO 2000028010 A3 WO2000028010 A3 WO 2000028010A3 EP 9907902 W EP9907902 W EP 9907902W WO 0028010 A3 WO0028010 A3 WO 0028010A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
diseases
prophylaxis
genes
therapy
Prior art date
Application number
PCT/EP1999/007902
Other languages
English (en)
French (fr)
Other versions
WO2000028010A2 (de
Inventor
Hans-Harald Sedlacek
Klaus Havemann
Rolf Mueller
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Priority to EP99953880A priority Critical patent/EP1127109A2/de
Priority to JP2000581177A priority patent/JP2002529080A/ja
Priority to CA002349497A priority patent/CA2349497A1/en
Priority to AU10407/00A priority patent/AU1040700A/en
Publication of WO2000028010A2 publication Critical patent/WO2000028010A2/de
Publication of WO2000028010A3 publication Critical patent/WO2000028010A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Die Erfindung bezieht sich auf ein Verfahren zur Herstellung von Zellen, die geeignet sind zur Behandlung des menschlichen Körpers, bei dem (a) Zellen dem menschlichen Körper entnommen werden; (b) die Zellen aus Schritt (a) in vitro mit mindestens einem Gen für einen Wachstums- und/oder Differenzierungsfaktor tranfiziert werden, welches unter der Kontrolle eines Promotors steht, so daß die Zellen aus Schritt (b) die Fähigkeit haben, nach der Rückführung in den menschlichen Körper in einer gewünschten Weise zu differenzieren; Zellen erhältlich nach diesem Verfahren und ihre Verwendung zur Herstellung eines Heilmittels zur Behandlung von Krankheiten.
PCT/EP1999/007902 1998-11-05 1999-10-19 Die gentechnische prägung von zellen und ihre verwendung zur prophylaxe und therapie von erkrankungen WO2000028010A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99953880A EP1127109A2 (de) 1998-11-05 1999-10-19 Die gentechnische prägung von zellen und ihre verwendung zur prophylaxe und therapie von erkrankungen
JP2000581177A JP2002529080A (ja) 1998-11-05 1999-10-19 細胞の遺伝子マーキングならびに疾病の予防および治療のためのその使用
CA002349497A CA2349497A1 (en) 1998-11-05 1999-10-19 The genetic determination of genes and its use for the prophylaxis and therapy of diseases
AU10407/00A AU1040700A (en) 1998-11-05 1999-10-19 The genetic determination of genes and its use for the prophylaxis and therapy of diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19850986A DE19850986A1 (de) 1998-11-05 1998-11-05 Die gentechnische Prägung von Zellen und ihre Verwendung zur Prophylaxe und Therapie von Erkrankungen
DE19850986.3 1998-11-05

Publications (2)

Publication Number Publication Date
WO2000028010A2 WO2000028010A2 (de) 2000-05-18
WO2000028010A3 true WO2000028010A3 (de) 2000-07-27

Family

ID=7886784

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/007902 WO2000028010A2 (de) 1998-11-05 1999-10-19 Die gentechnische prägung von zellen und ihre verwendung zur prophylaxe und therapie von erkrankungen

Country Status (6)

Country Link
EP (1) EP1127109A2 (de)
JP (1) JP2002529080A (de)
AU (1) AU1040700A (de)
CA (1) CA2349497A1 (de)
DE (1) DE19850986A1 (de)
WO (1) WO2000028010A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0015761D0 (en) * 2000-06-27 2000-08-16 Univ Bristol Polypeptide
US6962982B2 (en) 2001-06-22 2005-11-08 Roche Diagnostics Corporation Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them
DE10158680B4 (de) * 2001-11-30 2004-04-08 Universitätsklinikum Hamburg-Eppendorf Verfahren zur ex vivo-Expansion und -Differenzierung von multipotenten Stammzellen
FR3018819A1 (fr) * 2014-03-19 2015-09-25 Univ Bourgogne Traitement de la reponse inflammatoire et dysimmunitaire

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019712A1 (en) * 1996-11-08 1998-05-14 St. Elizabeth's Medical Center Of Boston, Inc. Methods for regulating angiogenesis
WO1998039427A2 (en) * 1997-03-06 1998-09-11 University Of Massachusetts Gene therapy using bone marrow transplants transfected with therapeutic genes under the control of tissue-specific promoters

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019712A1 (en) * 1996-11-08 1998-05-14 St. Elizabeth's Medical Center Of Boston, Inc. Methods for regulating angiogenesis
WO1998039427A2 (en) * 1997-03-06 1998-09-11 University Of Massachusetts Gene therapy using bone marrow transplants transfected with therapeutic genes under the control of tissue-specific promoters

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ASAHARA T ET AL: "ISOLATION OF PUTATIVE PROGENITOR ENDOTHELIAL CELLS FOR ANGIOGENESIS", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 275, 14 February 1997 (1997-02-14), pages 964 - 967, XP002059361, ISSN: 0036-8075 *
HAVEMANN K ET AL: "Generation of endothelial cells from CD34/CD14-positive mononuclear cells of human peripheral blood.", 89TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH;NEW ORLEANS, LOUISIANA, USA; MARCH 28-APRIL 1, 1998, vol. 39, March 1998 (1998-03-01), Proceedings of the American Association for Cancer Research Annual Meeting March, 1998, pages 61, XP002135753, ISSN: 0197-016X *

Also Published As

Publication number Publication date
DE19850986A1 (de) 2000-05-25
AU1040700A (en) 2000-05-29
CA2349497A1 (en) 2000-05-18
JP2002529080A (ja) 2002-09-10
WO2000028010A2 (de) 2000-05-18
EP1127109A2 (de) 2001-08-29

Similar Documents

Publication Publication Date Title
US5698436A (en) Introduction and expression of foreign genetic material in epithelial cells
UA86350C2 (en) Normal;heading 1;heading 2;MAMMALIAN CYTOKINE-LIKE POLYPEPTIDE-10
IL192078A0 (en) Recombinant ??-l-iduronidase,methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
WO1998011243A3 (en) Expression of an exogenous gene in a mammalian cell by use of a non-mammalian dna virus having an altered coat protein
MX9705039A (es) Genes y proteinas de muerte celular programada.
CA2098849A1 (en) Control of gene expression by ionizing radiation
AU6989094A (en) Compositions and methods for treating cancer and hyperproliferative disorders
CA2155024A1 (en) Genetic Modification of Neural Stem Cells
MY134810A (en) Targeted gene expression of thrombopoietein, dnase i and b-interferon
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
HU905679D0 (en) Process for producing new units suitable for treating cancerous illnesses and pharmaceutical preparatives containing them
AU7945682A (en) Rennin from recombinant dna
EP0568537A4 (de) Genetische veränderung von endothelzellen.
EP0266190A3 (en) Expression of protein c
AU5817496A (en) Process for producing erythropoietin containing no animal pr oteins
AU5455386A (en) Neovascularization inhibitors and methods for their production and use
WO1997013866A3 (en) Recombinant herpes virus vectors for expression in neuronal cells
DE60030324D1 (de) Replikationsunfähige herpesviren zur verwendung in gentherapie
CA2253287A1 (en) A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium
EP1616960A3 (de) Menschliche Pancreas Zellinien: Entwicklungen und Anwendungen
WO2003025151A3 (en) Circadian control of stem/progenitor cell self-renewal and differentiation and of clock controlled gene expression
WO1997022695A3 (fr) Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer
KR920004570A (ko) 사람 mk 단백질을 암호하는 유전자, 이를 포함하는 발현 벡터 및 숙주 세포, mk단백질의 생산 방법 및 사용방법
WO2000028010A3 (de) Die gentechnische prägung von zellen und ihre verwendung zur prophylaxe und therapie von erkrankungen
WO2002096195A8 (en) Treatment or replacement therapy using transgenic stem cells delivered to the gut

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 10407

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999953880

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 581177

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2349497

Country of ref document: CA

Ref country code: CA

Ref document number: 2349497

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1999953880

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999953880

Country of ref document: EP